Lurbinectedin plus paclitaxel for previously treated small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding lurbinectedin to paclitaxel (a standard chemo drug) helps people with small cell lung cancer that has progressed after prior treatment. You would receive either the combination or paclitaxel alone, and the study compares how well each works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 19 or older
- Diagnosis of extensive-stage (spread) small cell lung cancer
- Cancer has progressed after at least one platinum-based chemotherapy (like cisplatin or carboplatin)
- Able to care for yourself (ECOG performance status 0-2)
- At least one measurable tumor that can be seen on scans
- Expected to live at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
This trial studies whether adding palliative (comfort-focused) radiation to the medicine lurbinectedin can better control extensive-stage small cell lung cancer. It may help reduce problems from tumors in places like bones and organs.
This trial tests a combination of two drugs—lurbinectedin and durvalumab—for people with extensive-stage small cell lung cancer who have already received initial treatment. The goal is to see if this combination can help control the cancer better.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
This clinical trial tests a drug called lurbinectedin, given alone or with avelumab (an immunotherapy), for people with small cell bladder cancer or similar high-grade neuroendocrine tumors that have spread. The goal is to see if combining these drugs helps shrink or control the cancer better.
This Phase 2 study tests the combination of trilaciclib and lurbinectidin in adults whose cancer has already been treated, including with certain standard medicines. It aims to see if this combination can shrink tumors or slow cancer growth.
Hear when a new Carcinoma, Small Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.